Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2/3 1Phase 1 1

Status

Unknown 5Recruiting 4Active not recruiting 2Terminated 1Not yet recruiting 1

Sponsor Class

OTHER 8INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Thoracic 4

Conditions

Carcinoma, Non-Small-Cell Lung 4

Interventions

pembrolizumab 241Carboplatin 167Injections 138Paclitaxel 119Gemcitabine 116Bevacizumab 112Cisplatin 105Docetaxel 82Cyclophosphamide 78Pemetrexed 76Capecitabine 69Fluorouracil 67Oxaliplatin 65Fulvestrant 57fludarabine 55Nivolumab 55Leucovorin 52Cetuximab 52130-nm albumin-bound paclitaxel 47Dexamethasone 46Rituximab 41atezolizumab 37venetoclax 35Drug Therapy 35toripalimab 34enzalutamide 34Irinotecan 34durvalumab 32Prednisone 32Letrozole 32

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Recruiting × INDUSTRY × aumolertinib × Clear all
NCT07183189 2026-04-14

A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3 Recruiting
576 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT07130916 2025-08-19

A Study of Aumolertinib in European Participants With Non-Small Cell Lung Cancer

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 1 Recruiting
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06417008 2025-08-01

A Study of HS-20117 Combined With Aumolertinib in Participants With Advanced Non-Squamous Non-Small Cell Lung Cancer

Hansoh BioMedical R&D Company

Phase 2/3 Recruiting
1,080 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04951635 2022-06-16

A Phase III Study to Assess the Effects of Almonertinib Following Chemoradiation in Patients With Stage III Unresectable Non-small Cell Lung Cancer

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Phase 3 Recruiting
150 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡